A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Latest Information Update: 26 Dec 2024
Price :
$35 *
At a glance
- Drugs Ascorbic acid (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; First in man
- 20 Dec 2024 Status changed from active, no longer recruiting to completed.
- 26 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2024.
- 19 Aug 2019 Results published in the Clinical Cancer Research